摘要
目的研究奥沙利铂和卡培他滨联合疗法在晚期结肠癌中的应用价值。方法以2016年9月至2018年1月本院接诊的晚期结肠癌病患46例为研究对象,采用电脑随机双盲法分成实验组和对照组,各23例。实验组实行奥沙利铂和卡培他滨联合治疗,对照组实行奥沙利铂和5-氟尿嘧啶联合治疗。分析两组白细胞介素-6等血清学指标的改善情况,比较不良反应发生率等指标。结果实验组的临床总有效率为86.96%,明显比对照组的56.52%高,组间差异有统计学意义(P<0.05)。实验组治疗后的白细胞介素-6和血清癌基因ras产物P21蛋白水平明显比对照组低,组间差异有统计学意义(P<0.05)。实验组治疗后的血清卵巢癌缺失基因蛋白水平为(25.61±3.24)μg/ml,比对照组的(17.42±2.31)μg/ml高,组间差异有统计学意义(P<0.05)。实验组的不良反应发生率为8.7%,同对照组的26.09%比较差异有统计学意义(P<0.05)。结论通过联合应用奥沙利铂和卡培他滨,可显著改善晚期结肠癌患者的白细胞介素-6等血清学指标,提高病情控制效果,减少药物不良反应发生风险,建议采纳。
Objective To study the value of oxaliplatin combined with capecitabine in the treatment of advanced colon cancer. Methods Fortysix patients with advanced colon cancer received in our hospital from September 2016 to January 2018 were randomly divided into two groups: experimental group and control group(n=23). The experimental group was treated with oxaliplatin and capecitabine, and the control group with oxaliplatin and 5-fluorouracil. The improvement of serum indexes such as interleukin-6 and the incidence of adverse reactions were analyzed. Results The total clinical effective rate of the experimental group was 86.96%, which was significantly higher than that of the experimental group(P<0.05). The levels of IL-6 and P21 protein of serum oncogene ras in the experimental group were significantly lower than those in the control group(P<0.05). The level of deletion gene protein of serum ovarian cancer was(25.61±3.24) μg/ml in the experimental group, which was higher than that of the control group,the difference was significant(P<0.05). The incidence of adverse reactions in the experimental group was 8.7, which was significantly different from that in the control group(P<0.05). Conclusion The combination of oxaliplatin and capecitabine can significantly improve the serum indexes such as interleukin-6 in patients with advanced colon cancer, improve the effect of disease control and reduce the risk of adverse drug reactions.
引文
[1]蒲东升.奥沙利铂联合卡培他滨治疗中老年晚期结肠癌的临床观察[J].中国老年学杂志,2011,31(9):1673-1674.
[2]李拥军,邓飞,张雪琴,等.XELOX和OLF化疗方案治疗老年晚期结肠癌的疗效及安全性[J].中国老年学杂志,2015(1):237-238.
[3]孙慧琼,薛立光,杜丽坤,等.伊立替康/奥沙利铂联合卡培他滨治疗晚期结肠癌的疗效比较[J].中外医疗,2016,35(19):152-153.
[4]陈文海,田逸,师彦敏,等.中西医结合治疗晚期结肠癌疗效观察[J].现代中西医结合杂志,2014,23(11):1172-1174.
[5]王景艳.卡培他滨联合奥沙利铂方案与氟尿嘧啶联合奥沙利铂方案治疗晚期结肠癌药物经济学研究[J].当代医学,2016,22(26):123-124.
[6]师广勇.卡培他滨加用奥沙利铂联合治疗晚期结肠癌的临床疗效和毒副作用分析[J].实用癌症杂志,2018,33(2):305-307.
[7]张瑞亮,李文见,姜统杰,等.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者疗效对比[J].癌症进展,2017,15(2):196-198.
[8]毛跃伟,杨松鹏,高磊,等.奥沙利铂联合卡培他滨治疗晚期结肠癌的临床研究[J].中国临床药理学杂志,2016,32(14):1286-1288,1292.
